X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Fresenius Kabi Onco. with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

FRESENIUS KABI ONCO. vs SUVEN LIFE - Comparison Results

FRESENIUS KABI ONCO.    Change

Fresenius Kabi Oncology is the erstwhile Dabur Pharma, which was incorporated in March 2003. The company is a leading player in oncology in India and the international markets. Fresenius Kabi Oncology operates in the regulated markets namely the US a... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    FRESENIUS KABI ONCO. SUVEN LIFE FRESENIUS KABI ONCO./
SUVEN LIFE
 
P/E (TTM) x 22.1 16.3 135.9% View Chart
P/BV x 3.1 3.9 80.5% View Chart
Dividend Yield % 0.0 0.5 -  

Financials

 FRESENIUS KABI ONCO.   SUVEN LIFE
EQUITY SHARE DATA
    FRESENIUS KABI ONCO.
Mar-13
SUVEN LIFE
Mar-17
FRESENIUS KABI ONCO./
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs176229 77.0%   
Low Rs79151 52.0%   
Sales per share (Unadj.) Rs37.742.7 88.2%  
Earnings per share (Unadj.) Rs5.16.9 74.4%  
Cash flow per share (Unadj.) Rs6.78.5 78.8%  
Dividends per share (Unadj.) Rs01.00 0.0%  
Dividend yield (eoy) %00.5 0.0%  
Book value per share (Unadj.) Rs42.552.4 81.2%  
Shares outstanding (eoy) m158.23127.28 124.3%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.44.4 76.0%   
Avg P/E ratio x25.027.7 90.2%  
P/CF ratio (eoy) x18.922.2 85.1%  
Price / Book Value ratio x3.03.6 82.6%  
Dividend payout %014.6 0.0%   
Avg Mkt Cap Rs m20,13524,158 83.3%   
No. of employees `0001.21.0 113.4%   
Total wages/salary Rs m703522 134.8%   
Avg. sales/employee Rs Th5,176.25,349.7 96.8%   
Avg. wages/employee Rs Th610.4513.5 118.9%   
Avg. net profit/employee Rs Th699.6858.1 81.5%   
INCOME DATA
Net Sales Rs m5,9635,435 109.7%  
Other income Rs m18211 8.5%   
Total revenues Rs m5,9815,646 105.9%   
Gross profit Rs m1,4301,291 110.8%  
Depreciation Rs m258214 120.5%   
Interest Rs m-2657 -45.8%   
Profit before tax Rs m1,2161,231 98.8%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-680-   
Tax Rs m342359 95.4%   
Profit after tax Rs m806872 92.4%  
Gross profit margin %24.023.7 101.0%  
Effective tax rate %28.129.2 96.5%   
Net profit margin %13.516.0 84.3%  
BALANCE SHEET DATA
Current assets Rs m5,1024,917 103.8%   
Current liabilities Rs m2,3851,186 201.1%   
Net working cap to sales %45.668.6 66.4%  
Current ratio x2.14.1 51.6%  
Inventory Days Days15062 241.5%  
Debtors Days Days11331 368.1%  
Net fixed assets Rs m5,1483,154 163.2%   
Share capital Rs m158127 124.3%   
"Free" reserves Rs m6,5566,543 100.2%   
Net worth Rs m6,7326,670 100.9%   
Long term debt Rs m952259 367.2%   
Total assets Rs m10,3888,157 127.3%  
Interest coverage x-45.822.7 -202.0%   
Debt to equity ratio x0.10 363.8%  
Sales to assets ratio x0.60.7 86.1%   
Return on assets %7.511.4 65.9%  
Return on equity %12.013.1 91.6%  
Return on capital %14.618.6 78.6%  
Exports to sales %74.50-   
Imports to sales %24.80-   
Exports (fob) Rs m4,441NA-   
Imports (cif) Rs m1,477NA-   
Fx inflow Rs m5,2984,996 106.0%   
Fx outflow Rs m1,772959 184.8%   
Net fx Rs m3,5254,037 87.3%   
CASH FLOW
From Operations Rs m1,2741,088 117.1%  
From Investments Rs m-1,204-3,107 38.8%  
From Financial Activity Rs m-196-300 65.3%  
Net Cashflow Rs m-126-2,319 5.4%  

Share Holding

Indian Promoters % 0.0 63.4 -  
Foreign collaborators % 81.0 0.0 -  
Indian inst/Mut Fund % 0.3 0.0 -  
FIIs % 9.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 9.1 36.5 24.9%  
Shareholders   42,599 37,287 114.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare FRESENIUS KABI ONCO. With:   ALEMBIC PHARMA  STRIDES SHASUN LTD  TTK HEALTHCARE  ASTRAZENECA PHARMA  BIOCON LTD  

Compare FRESENIUS KABI ONCO. With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends Day up 260 Points; Pharma Stocks Top Gainers(Closing)

After opening the day in red, share markets in India witnessed positive trading activity throughout the day and ended the day on a positive note.

Related Views on News

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Has the Market Bottomed Out?(Sector Info)

Jun 11, 2018

The yield spread is an effective barometer that can indicate the direction the markets are headed.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

FRESENIUS KABI ONCO. SHARE PRICE


Jan 2, 2014 (Close)

TRACK FRESENIUS KABI ONCO.

  • Track your investment in FRESENIUS KABI ONCO. with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON FRESENIUS KABI ONCO.

FRESENIUS KABI ONCO. - ALKEM LABORATORIES COMPARISON

COMPARE FRESENIUS KABI ONCO. WITH

MARKET STATS